Treatment of renal osteodystrophy

被引：1
作者：
Gal-Moscovici A. [1 ,2 ]
Sprague S.M. [2 ,4 ]
Lerma E.V. [3 ]
机构：
[1] Hadassah Hospital Medical Center, Hebrew University, Ein Keren, Jeruslaem
[2] Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
[3] Section of Nephrology, University of Illinois at Chicago, College of Medicine/Associates in Nephrology, Chicago, IL
[4] Evanston, IL 60201
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2007年 / 5卷 / 1期
关键词：
Cinacalcet; Parathyroidectomy; Phosphate binders; Renal osteodystrophy; Vitamin D receptor agonist;
D O I：
10.1007/BF02736669
中图分类号：
学科分类号：
摘要：
Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist's concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy. © Copyright 2007 by Humana Press Inc. All rights of any nature whatsoever reserved.
引用
收藏
页码：27 / 38
页数：11
相关论文
共 115 条
  • [1] US Renal Data system, USRDS 2004 Annual data report, (2004)
  • [2] Massry S.G., Smogorzewski M., Mechanism to which parathyroid hormone mediates its deleterious effects on organ function in uremia, Semin Nephrol, 14, pp. 219-231, (1994)
  • [3] Silver J., Kilav R., Naveh-Many T., Mechanisms of secondary hyperparathyroidism, Am J Physiol Renal Physiol, 283, (2002)
  • [4] Block J.A., Hulbert-Shearon T.E., Levin N.W., Port F.K., Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study, Am J Kidney Dis, 31, pp. 607-617, (1998)
  • [5] Llach F., Yudd M., The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure, Nephrol Dial Transplant, 13, SUPPL. 13, pp. 57-61, (1998)
  • [6] Malluche H.H., Monier-Faugere M.C., Understanding and managing hyperphosphatemia in patients with chronic renal failure, Clin Nephrol, 52, pp. 267-277, (1999)
  • [7] Shigematsu T., Kazama J.J., Yamashita T., Et al., Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency, Am J Kidney Dis, 44, pp. 250-256, (2004)
  • [8] Inaba M., Nakatsuka K., Nagasue K., Et al., FGF-23 in patients with end-stage renal disease on hemodialysis, Kidney Int, 65, pp. 1943-1946, (2004)
  • [9] Fukuda N., Tanaka H., Tominaga Y., Et al., Decreased 1,25- dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients, J Clin Invest, 92, pp. 1436-1443, (1993)
  • [10] Gogusev J., Duchambon P., Hory B., Et al., Depressed expression of calcium receptor in parathyroid gland Tissue of patients with hyperparathyroidism, Kidney Int, 51, 1, pp. 328-336, (1993)
12345678910